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Abstract
Background: Circulating Sex hormone binding globulin (SHBG) levels are inversely associated with insulin resistance.
This study was conducted to compare maternal serum SHBG level between pregnant women with normal glucose
tolerance and those with gestational diabetes (GDM) and to investigate the roll of SHBG in GDM diagnosis.
Methods: This was a case controlled study of 90 pregnant women, 45 women with GDM and 45 matched controls,
attending obstetrics clinic at Ohud Hospital, Madina, Saudi Arabia between April 2014 and March 2015. Measurement
of serum SHBG levels by Enzyme-linked immunosorbent assay (ELISA) method were done between 24 and 28 weeks
of gestation. The best cut-off point of SHBG to diagnose GDM was calculated in receiver operating characteristic curve.
Results: Compared with the control group, SHBG concentrations were significantly lower in the GDM group; median
23 nmol/L (18–30) vs. 78 nmol/L (65–96), p < 0.001). The cut off value 50 nmol/L of the SHBG had 90% sensitivity and
96% specificity to diagnose GDM.
Conclusion: Patients with GDM have lower circulating levels of SHBG than normal glucose tolerance pregnant
women. Circulating concentrations of SHBG represent a potentially useful new biomarker for prediction of risk of GDM
beyond the currently established clinical and demographic risk factors.
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Background
Sex hormone-binding globulin (SHBG) is a glycoprotein
produced by the liver that binds sex steroids in the
circulation. Secretion is suppressed by insulin, and low
levels of SHBG are frequently observed in states of
insulin resistance and have been studied as a potential
predictor of the development of T2DM [1, 2].
Insulin resistance is the hallmark of gestational diabetes
mellitus (GDM) and it is pathogenically related to T2DM.
SHBG levels were reported to be lower in women with
gestational diabetes and in those who require insulin
therapy [3–7]. In addition, women with a reduced concen-
tration of SHBG in the first trimester of pregnancy are at
increased risk of developing gestational diabetes later in
pregnancy [7–9].
GDM is a common pregnancy complication and is
associated with increased maternal and neonatal morbidity.
Identifying and treating women with GDM is important to
improve the outcomes. The definitive diagnostic testing for
GDM is an oral glucose tolerance test. Such test requires
fasting of at least 8 h, needs 3–4 blood samplings and re-
quires 2–3 h to be completed. SHBG is simple, inexpensive
blood test that can be performed in the non-fasting state,
[10] with no diurnal variation, [11]. This makes SHBG a
valuable marker for GDM diagnosis. The aim of this study
is to compare maternal serum SHBG level between GDM
and normal glucose tolerant women and to investigate the
roll of SHBG in GDM diagnosis.* Correspondence: Manalhammoda1965@yahoo.com
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Methods
The study was a hospital based case control study that
involved pregnant women followed at the antenatal
service of the outpatient clinic at Ohud Hospital, Madina,
Saudi Arabia between April 2014 and March 2015. A total
of 55 pregnant women with GDM were enrolled in the
study between 24 and 28 weeks’ of gestation. The diagno-
sis of GDM in Ohud hospital is based on the international
Association of Diabetes and Pregnancy Study Groups
(IADPSG) consensus panel [12]. Women with pre-
gestational diabetes mellitus, preeclampsia or gestational/
chronic hypertension (systolic blood pressure >140 mmHg
and diastolic blood pressure >90 mmHg), multiple preg-
nancies and patients with poly cystic ovary syndrome
(PCOS) were excluded from the study. After the exclusion
of ten women, forty five women with GDM were included
in the study and were matched with 45 pregnant controls
of similar age, weight, height and body mass index(BMI).
Maternal age, weight, height, BMI and blood pressure
were recorded. Blood samples were collected from the
participants at 24–28 weeks’ of gestation into non- heparin-
ized tubes. Then the blood sample was centrifuged at
3000 rpm for 10 min within 20 min of the blood draw and
then separated and divided into two samples, one for
analysis of the biochemical parameters and the other was
frozen at -20 C until assayed for SHBG analyses.
For the measurement of biochemical parameters the
sample was placed on ice and transported to the clinical
laboratory in a cooler with an ice block within 2–4 h of
being drawn, and the serum glucose concentration was
measured in mg/dl by the glucose oxidase method and
serum cholesterol concentration was measured by colori-
metric method. SHBG was measured by a quantitative
sandwich enzyme-linked immunoassay (ELISA) technique.
The kit for SHBG analysis was supplied by DIA source
Immuno Assays SA- Rue du Bosquet 2, B-1348 Louvain-la
-Neuve, Belgium. The analytical sensitivity of the DIA
source ELISA was found to be 0.77 nmol/L.
Statistical analyses
Data analysis was performed using SPSS for Windows,
version 20. Whether the distributions of continuous
variables were normal or not was determined by the
Shapiro–Wilk test. Data are shown as mean ± SD or
median (Interquartile range), where applicable. The
mean differences between groups were compared by
Student’s t-test; otherwise the Mann–Whitney U-test
was applied for the comparisons of the median values.
Degrees of association between continuous variables
were calculated by Spearman’s rank correlation analyses.
The ability of SHBG value to detect GDM was exam-
ined by the receiver operating characteristic (ROC)
curve and their respective areas under the curve, in
which sensitivity is plotted as a function of 1-specificity.
The optimal cut-off points with highest sensitivity and
specificity were evaluated. A P-value less than 0.05 was
considered statistically significant.
Results
A total of 90 pregnant women were included in the
study, 45 women with GDM and 45 matched controls
(Non-GDM). Maternal baseline characteristics are shown
in (Table 1). There were no significant differences between
the two groups with regards to age, weight, height, BMI,
and blood pressure.
Women with GDM had higher levels of random blood
glucose(RBG) and cholesterol than the control group, P=
0.001 (Table 1). SHBG concentration was found to be signifi-
cantly lower in the GDM group; median 23 nmol/L (18–30)
than in control group 78 nmol/L (65–96), P= 0.001, (Fig. 1).
There was significant negative correlation between the levels
of SHBG and RBG and cholesterol levels (Table 2 & Fig. 2).
The predictive accuracy of SHBG as a marker for
GDM was determined by receiver operator curve (ROC)
analysis (AUC: 0.913; 95% CI: 0.822-1.005). The cutoff
value 50 nmol/L of the SHBG had 90%, sensitivity, 96%
specificity, 95% positive predictive values and 89% nega-
tive predictive values, (Fig. 3).
Discussion
SHBG is important for the transport and regulation of sex
hormones. It is secreted in the liver under hormonal and
nutritional control. Secretion is suppressed by insulin, and
low levels of SHBG are frequently observed in states of
insulin resistance and have been studied as a potential
predictor of the development of T2DM [1, 2]. In normal
pregnancy, SHBG levels rise progressively until 24 weeks
of gestation [13, 14]. Subsequently, the level of SHBG sta-
bilizes and this may be attributable to the hyperinsuline-
mia and insulin resistance that increase progressively from
the late second trimester [15, 16]. GDM is a state of insu-
lin resistance in pregnancy that seems to result from simi-
lar mechanisms in type 2 diabetes mellitus. Sex hormone-








Age (years) 29.27 ± 6.87 26.84 ± 6.99 0.101
Weight (Kg) 72.84 ± 8.79 70.84 ± 8.39 0.273
Height (cm) 158.42 ± 6.31 159.40 ± 5.15 0.423
BMI (Kg/m2) 30.73 ± 4.82 29.56 ± 3.66 0.198
SBP (mmHg) 121.64 ± 6.28 120.33 ± 6.25 0.324
DBP (mmHg) 73.42 ± 2.83 72.82 ± 2.57 0.295
Serum Cholesterol (mg/dl) 174.56 ± 12.71 158.71 ± 8.96 0.001
RBG (mg/dl) 93.24 ± 4.64 83.91 ± 4.12 0.001
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binding globulin has emerged as one of the biochemical
marker for GDM diagnosis [3–9].
In the current study, we found women with GDM had
significantly lower levels of SHBG concentrations com-
pared to Non GDM women at 24–28 weeks of pregnancy.
This finding is consistent with results from previous stud-
ies [3–9]. Furthermore, lower first-trimester SHBG levels
were found to predict subsequent gestational diabetes
mellitus [7–9]. Moreover, SHBG were reported to be
lower in women with GDM requiring insulin compared to
those with medical nutritional therapy alone. On the basis
of these results, it was suggested measuring SHBG early in
gestation could have a potential benefit in prediction of
severe GDM [7]. This might overcome the limitation of
the current recommendation for GDM diagnosis which
recommend screening at 24 to 28 weeks of gestation that
leaves a narrow window during which interventions can
be applied before delivery. Earlier identification and treat-
ment of pregnancies with, or at risk for, GDM with SHBG
might present a good option to improve outcomes. On
the same manner, preconception SHBG levels in women
with PCOS were reported to be strongly associated with
subsequent development of GDM. PCOS is associated
with insulin resistance which will be augmented by the
hormones of pregnancy that counter the action of insulin.
Therefore, measuring SHBG pre conception was sug-
gested to be a screening tool of women at higher risk of
developing GDM during pregnancy [17]. Furthermore,
lower SHBG levels were reported to be associated with
higher fasting blood glucose levels among women with
recent GDM, a high-risk population for diabetes, and this
association was independent of potential confounders
[18]. Thus, SHBG might be a useful marker in predicting
T2DM development in women with recent GDM,
however, this requires further testing.
Fig. 1 Difference in the median sex hormone binding globulin levels between gestational diabetes mellitus and the control groups
Table 2 Correlations between maternal parameters and SHBG










r p r p R p
Age 0.075 0.626 - 0.019 0.899 - 0.128 0.228
BMI 0.253 0.094 - 0.101 0.508 - 0.112 0.291
RBG - 0.126 0.409 0.008 0.961 - 0.538 0.001*
Serum cholesterol -0.210 0.166 - 0.320 0.032* - 0.547 0.001*
*p value is significant
Fig. 2 Correlation between random blood glucose levels and sex
hormone binding globulin levels in the studied groups
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Conclusion
Patients with GDM have a lower circulating level of
SHBG than normal glucose tolerance pregnant women.
Circulating concentrations of SHBG represent a poten-
tially useful new biomarker identifying GDM beyond the
currently established biochemical markers. A standard
assay for serum SHBG analyses and a gestational trimes-
ter threshold level have to be determined.
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